Vascular Biogenics Ltd.

Symbol: VBLT




Market price today

  • -0.9717

    P/E Ratio

  • 0.0228

    PEG Ratio

  • 12.11M

    MRK Cap

  • 0.00%

    DIV Yield

Vascular Biogenics Ltd. (VBLT) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Prof. Dror Harats M.D.
Full-time employees:7
City:Hevel Modi'in
Address:8 HaSatat Street

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

General Outlook

In simple terms, Vascular Biogenics Ltd. has 77.64 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.971% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -114.530%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -21.189%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.511% return, is a testament to Vascular Biogenics Ltd.'s adeptness in optimizing resource deployment. Vascular Biogenics Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.579%. Furthermore, the proficiency of Vascular Biogenics Ltd. in capital utilization is underscored by a remarkable -3.517% return on capital employed.

Stock Prices

Vascular Biogenics Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.219, while its low point bottomed out at $0.2036. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Vascular Biogenics Ltd.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Vascular Biogenics Ltd. (VBLT) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -0.972 in 2023.

What is the ticker symbol of Vascular Biogenics Ltd. stock?

The ticker symbol of Vascular Biogenics Ltd. stock is VBLT.

What is company IPO date?

IPO date of Vascular Biogenics Ltd. is 2014-10-01.

What is company current share price?

Current share price is 0.156 USD.

What is stock market cap today?

The market cap of stock today is 12111917.000.

What is PEG ratio in 2023?

The current 0.023 is 0.023 in 2023.

What is the number of employees in 2023?

In 2023 the company has 7.